Matisse Capital’s Verona Pharma VRNA Stock Holding History

Matisse Capital’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,294	Closed	-$974K	–	182
2025 Q2	$974K	Sell	10,294 -3,500	-25%	-$259K	0.46%	72
2025 Q1	$876K	Sell	13,794 -606	-4%	-$36.2K	0.46%	71
2024 Q4	$669K	Sell	14,400 -9,000	-38%	-$338K	0.34%	91
2024 Q3	$673K	Sell	23,400 -11,000	-32%	-$271K	0.33%	95
2024 Q2	$497K	Buy	34,400 +15,000	+77%	+$219K	0.25%	115
2024 Q1	$312K	Buy	+19,400	New	+$335K	0.15%	146

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Matisse Capital's VRNA Position: Q3 2025 in Review

Matisse Capital sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 10,294 shares — an estimated $974K sold.

Matisse Capital first reported a position in VRNA in Q1 2024 and held it in 6 quarters. The position peaked at $974K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Matisse Capital reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Matisse Capital sold 10,294 Verona Pharma shares in Q3 2025, an estimated $974K.
Matisse Capital first reported a position in Verona Pharma in Q1 2024 and held it in 6 quarters.
Matisse Capital's Verona Pharma position peaked at $974K in Q2 2025.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Matisse Capital's 13F filing for Q3 2025, filed 29 Oct 2025.